Merck KGaA received a reaffirmed neutral rating, reduced its stake by 18.5%, and filed 13F reports with the SEC.
1 report, 1 independent
Updated Jul 25
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Merck KGaA received a reaffirmed neutral rating, reduced its stake by 18.5%, and filed 13F reports with the SEC.
Who's involved
What this event is mainly aboutKeep exploring
The entities involved
-
Merck KGaA
German multinational science and technology company
-
Cantor Fitzgerald
American financial services company
-
Securities and Exchange Commission
government agency of the Philippines
Related events
- Filing regarding a stake purchase with the SEC shows First Horizon Corporation acquired a new stake, with Goldman Sachs setting a $27.00 price target.
- Cantor Fitzgerald raised its price target and rating for Supernus Pharmaceuticals, Inc. on September 2, 2026, and the company filed a disclosure with the SEC.
- Peak Asset Management acquired a new stake in Booking Holdings and received rating updates from HSBC and JPMorgan.
- Trustmark executed a sale-leaseback and filed an 8-K with the SEC, while Western Alliance and Zions Bancorp reflect regional banking sector anxieties.
- Cantor Fitzgerald restated an overweight rating on shares, while J. Goldman & Co LP purchased a new stake in Annexon. Disclosure was made to the Securities and Exchange Commission.
Coverage
Newest first; wire copies grouped- tickerreport.comHilltop Holdings Inc. Trims Stock Holdings in Merck & Co., Inc. $MRK